Aytu BioPharma reported a mixed QQ3 2024, with a pronounced shift toward a pure-play Rx business strategy following the wind-down of the Consumer Health segment. Net revenue declined 21% year over year to $18.0 million, pressured by the ongoing Consumer Health wind-down (down to $4.0 million from $8.9 million in the prior-year quarter) even as ADHD portfolio net revenue grew 49% YoY to $12.3 million, underscoring the strength and scalability of the ADHD franchise and the RxConnect support infrastructure. Management framed the results as part of a deliberate strategic transformation aimed at higher profitability, lower cash burn, and eventual free cash flow generation, aided by manufacturing outsourcing, the closure of the Texas facility, and a refinery of the cost base. On a trailing-12-month basis, company-wide adjusted EBITDA exceeded $15 million, with Rx segment operating income over that period above $7 million, illustrating meaningful margin resilience in the core business despite the legacy wind-down. Management emphasized ongoing margin expansion (Rx gross margins rose to 74% from 61% YoY) and the successful integration of a new distributor to enhance RxConnect’s stickiness, while acknowledging near-term liquidity considerations and refinancing initiatives tied to a maturing term loan in January 2025. The company projects a constructive trajectory as the Consumer Health exit completes and the ADHD manufacturing transition completes, positioning Aytu to pursue growth, margin expansion, and cash-flow generation in fiscal 2025. However, investors should monitor execution risk associated with the wind-down cadence, payer dynamics (especially pediatric coverage), potential supply shocks in ADHD channels, and the timing of refinancing milestones.